GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIO) » Definitions » E10

XBIO (Xenetic Biosciences) E10 : $-232.89 (As of Jun. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Xenetic Biosciences E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Xenetic Biosciences's adjusted earnings per share data for the three months ended in Jun. 2024 was $-0.830. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-232.89 for the trailing ten years ended in Jun. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-09-21), Xenetic Biosciences's current stock price is $3.92. Xenetic Biosciences's E10 for the quarter that ended in Jun. 2024 was $-232.89. Xenetic Biosciences's Shiller PE Ratio of today is .


Xenetic Biosciences E10 Historical Data

The historical data trend for Xenetic Biosciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenetic Biosciences E10 Chart

Xenetic Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -271.93 -271.53 -252.84

Xenetic Biosciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -264.57 -260.12 -252.84 -241.82 -232.89

Competitive Comparison of Xenetic Biosciences's E10

For the Biotechnology subindustry, Xenetic Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenetic Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's Shiller PE Ratio falls into.



Xenetic Biosciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xenetic Biosciences's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.83/132.5538*132.5538
=-0.830

Current CPI (Jun. 2024) = 132.5538.

Xenetic Biosciences Quarterly Data

per share eps CPI Adj_EPS
201409 -79.200 100.428 -104.535
201412 -158.401 99.070 -211.938
201503 -79.200 99.621 -105.382
201506 -32.400 100.684 -42.656
201509 -151.201 100.392 -199.641
201512 -103.200 99.792 -137.080
201603 -93.600 100.470 -123.489
201606 -734.403 101.688 -957.319
201609 -33.600 101.861 -43.724
201612 -36.000 101.863 -46.847
201703 -40.800 102.862 -52.577
201706 -40.800 103.349 -52.329
201709 -31.200 104.136 -39.714
201712 62.400 104.011 79.524
201803 -25.200 105.290 -31.725
201806 -27.800 106.317 -34.661
201809 -23.100 106.507 -28.749
201812 -20.800 105.998 -26.011
201903 -64.500 107.251 -79.717
201906 -15.600 108.070 -19.134
201909 -26.700 108.329 -32.671
201912 -1.929 108.420 -2.358
202003 -1.900 108.902 -2.313
202006 -1.500 108.767 -1.828
202009 -12.000 109.815 -14.485
202012 -1.500 109.897 -1.809
202103 -1.500 111.754 -1.779
202106 -1.300 114.631 -1.503
202109 -1.300 115.734 -1.489
202112 -1.400 117.630 -1.578
202203 -1.200 121.301 -1.311
202206 -1.900 125.017 -2.015
202209 -0.560 125.227 -0.593
202212 -0.970 125.222 -1.027
202303 -0.560 127.348 -0.583
202306 -0.690 128.729 -0.711
202309 -0.690 129.860 -0.704
202312 -0.770 129.419 -0.789
202403 -0.780 131.776 -0.785
202406 -0.830 132.554 -0.830

Add all the adjusted EPS together and divide 10 will get our e10.


Xenetic Biosciences  (NAS:XBIO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Xenetic Biosciences E10 Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenetic Biosciences Business Description

Traded in Other Exchanges
N/A
Address
945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Executives
Grigory G. Borisenko director 40 SPEEN STREET, SUITE 102, FRAMINGHAM MA 01701
Alexey Andreevich Vinogradov director C/O XENETIC BIOSCIENCES, INC., 40 SPEEN STREET, FRAMINGHAM MA 01701
Adam Logal director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
James Eric Callaway director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Dmitry Genkin director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
James F Parslow officer: Chief Financial Officer C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Curtis Lockshin officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Roger D. Kornberg director 345 WALSH ROAD, ATHERTON CA 94027
Darlene M Deptula-hicks director C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Jeffrey F Eisenberg director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Firdaus J. Dastoor director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Michael Scott Maguire director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Roman Knyazev director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Pharmsynthez Pjsc 10 percent owner 25 LITER KRASNOVO KURSANTA STREET, ST. PETERSBURG 1Z 197110

Xenetic Biosciences Headlines

From GuruFocus